Gene Expression Outcomes in Interventions for Substance Using HIV+ Minority Men
1 other identifier
interventional
40
1 country
1
Brief Summary
This is a pilot study of a new 9-session individually delivered cognitive behavioral intervention targeting sexual minority stress. In this study, 40 HIV+ men sexual minority men will be recruited for the study then will be randomly assigned to either the new 9 session intervention or a writing task condition.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for not_applicable
Started May 2017
Typical duration for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
May 2, 2017
CompletedStudy Start
First participant enrolled
May 5, 2017
CompletedFirst Posted
Study publicly available on registry
May 8, 2017
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 1, 2018
CompletedStudy Completion
Last participant's last visit for all outcomes
March 8, 2019
CompletedOctober 22, 2024
April 1, 2024
1.6 years
May 2, 2017
October 18, 2024
Conditions
Outcome Measures
Primary Outcomes (1)
Change in Gene expression
Gene expression related to inflammation measured in blood
Baseline, ~9 weeks (at conclusion of intervention), 4 month follow-up
Secondary Outcomes (1)
Change in Substance Use
Baseline, ~9 weeks (at conclusion of intervention), 4 month follow-up
Study Arms (2)
AWARENESS for sexual minorities
EXPERIMENTALGroup receives new CBT-based intervention
Writing tasks
ACTIVE COMPARATORGroup receives writing-based sessions
Interventions
9 session, individually delivered, cognitive behavioral intervention focused on modifying sexual minority stress responses to reduce the impact of sexual minority stress experiences.
Eligibility Criteria
You may qualify if:
- Provide evidence or documentation of HIV positive status (e.g. a letter of diagnosis or medication bottles with matched photo ID)
- Be English speaking
- Be able to consent
- Sexual activity with a man in the 3 years prior to initial contact or identification as gay or bisexual
- Not currently be enrolled in formal substance abuse treatment
- Report at least one occasion of drinking 5 or more drinks or of using an illicit substance in the previous 3 months, but not meet criteria for a severe substance use disorder.
You may not qualify if:
- Presence of a severe substance use disorder
- Presence of current symptoms consistent with schizophrenia or bipolar disorder, which would indicate that an intervention targeting these symptoms would be more appropriate.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
University of California, San Francisco
San Francisco, California, 94143, United States
Related Publications (1)
Flentje A, Sunder G, Carrico AW, Asam K, Neilands TB, Lisha NE, Dilley J, Flowers E, Kober K, Aouizerat B. Differential gene expression in response to AWARENESS: A randomized controlled trial of an intersectional minority stress intervention. Health Psychol. 2025 Mar;44(3):291-296. doi: 10.1037/hea0001451.
PMID: 39992775DERIVED
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- SINGLE
- Who Masked
- OUTCOMES ASSESSOR
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
May 2, 2017
First Posted
May 8, 2017
Study Start
May 5, 2017
Primary Completion
December 1, 2018
Study Completion
March 8, 2019
Last Updated
October 22, 2024
Record last verified: 2024-04